The invention provides a PIM kinase inhibitor with a structural formula as a compound represented as a formula I. The invention also provides an isomer, a non-enantiomer, an enantiomer, a tautomer, and a salt of the compound represented by the formula I. In the formula I, E, J, Q, X, Y, Z, and m are defined as in the Claim 1. As a result of a PIM kinase biochemical activity test method, the compound (1-122) provided by the invention has a substantial inhibiting effect against PIM-1 kinase activity. Under a concentration of 3mumol, a PIM-1 kinase activity inhibiting rate exceeds 50%, and can reach a maximal value of 100%. All preferred compounds have equivalent inhibiting effect against PIM-2 and PIM-3 kinase activities. When a compound concentration is 3mumol, maximal values of PIM-2 and PIM-3 kinase activity inhibiting rates reach 100%. Therefore, the PIM kinase inhibitor provided by the invention can be applied in preparing medicines used for treating or preventing cancers, autoimmune diseases, allergic reaction diseases, or organ transplant rejection. The PIM kinase inhibitor has great clinical application values. The invention also provides a preparation method of the PIM kinase inhibitor.